{"id":"NCT02616029","sponsor":"Gilead Sciences","briefTitle":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","officialTitle":"A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adult Subjects Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-17","primaryCompletion":"2018-10-11","completion":"2019-07-11","firstPosted":"2015-11-26","resultsPosted":"2019-11-04","lastUpdate":"2020-07-23"},"enrollment":66,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1 Infection"],"interventions":[{"type":"DRUG","name":"E/C/F/TAF","otherNames":["GenvoyaÂ®"]}],"arms":[{"label":"Part 1: E/C/F/TAF","type":"EXPERIMENTAL"},{"label":"Part 2: E/C/F/TAF","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) after switching from a stable regimen consisting of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine (ABC/3TC) plus a third antiretroviral (ARV) agent in participants harboring the archived nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance mutation M184V and/or M184I in human immunodeficiency virus (HIV) -1 reverse transcriptase.\n\nThis is a two part study. If the rate of virologic failure in Part 1 is deemed acceptable, once the internal data monitoring committee officially completes the interim review, the study will continue to Part 2.","primaryOutcome":{"measure":"Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 12 as Defined by Pure Virologic Response (PVR)","timeFrame":"Week 12","effectByArm":[{"arm":"Part 1: E/C/F/TAF","deltaMin":100,"sd":null},{"arm":"Part 2: E/C/F/TAF","deltaMin":100,"sd":null},{"arm":"Total E/C/F/TAF","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":8},"locations":{"siteCount":21,"countries":["United States","France","Germany","Italy","Spain"]},"refs":{"pmids":["33315694"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":64},"commonTop":["Asthenia","Bronchitis","Nasopharyngitis","Headache","Diarrhoea"]}}